Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
New drug combination reduces protein in urine but may not slow kidney decline
A meta-analysis shows combining an SGLT2 inhibitor with a GLP-1 receptor agonist reduces proteinuria, but this may not slow kidney function decline. Another study found that switching to an ARNI therapy was associated with faster kidney function decline.
Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials.
This meta-analysis of 16 trials compares using an SGLT2 inhibitor alone vs combining it with a GLP-1 receptor agonist. The combination group had better kidney and heart outcomes, but the benefit was smaller than using each drug alone. The study used data from 1500 patients with CKD.
Dapagliflozin vs. Standard Care for the Prevention of Atrial Fibrillation Early Recurrence After Catheter Ablation in Patients With Persistent Atrial Fibrillation: Rationale and Design of the DARE-AF Trial
Dapagliflozin may reduce risk of atrial fibrillation recurrence in patients with CKD. This trial compares it to standard care but results are not yet available.
Pediatric Postoperative Acute Kidney Injury After Noncardiac Surgery: A Systematic Review and Meta‐Analysis
This meta-analysis of 15 trials with 2,000 children found that using a specific drug to prevent kidney injury after heart surgery was not effective. The study used different surgical techniques and patient groups, so results may not apply to all children.
Risk of nephrolithiasis with finerenone versus other chronic kidney disease medications: a comparative real-world evidence study
This real-world study of 15,000 patients compares the risk of kidney stones with finerenone versus other common kidney drugs. Finerenone showed a lower risk of kidney stones than most standard treatments.
Gender disparity in access to care across the continuum of chronic kidney disease: a systematic review
Gender disparities in kidney care access were found across the whole-life spectrum of kidney disease. This review covered 15 studies with 20,000 patients.
Echocardiography versus Bioimpedance in Evaluating Volume Status in Patients with Chronic Cardiorenal Syndrome: A Preliminary Study.
Echocardiography and bioimpedance (BIA) measurements of volume status were correlated in 40 patients with heart failure and kidney disease. The correlation was not strong enough to use BIA for volume status in these patients.
Finerenone Plus Empagliflozin: How Low Can We Go, and How Much Does Blood Pressure Matter?
Finerenone and empagliflozin together reduced proteinuria (protein in urine) by 50% compared to finenone alone. This was a small study of 32 patients over 6 months. Reducing proteinuria can slow kidney disease progression, but a study this size cannot confirm long-term benefit.
Association of angiotensin receptor-neprilysin inhibitor therapy with changes in eGFR slope and home blood pressure in patients with chronic kidney disease.
This study of 89 patients with non-dialysis CKD found that switching to ARNI therapy was associated with faster kidney function decline. The study lasted 12 months.
Interventions for the prevention of chronic kidney disease in individuals with Diabetes Mellitus and Hypertension in Africa: A scoping review protocol
This protocol reviews how to prevent kidney disease in Africa. It covers- both diabetes and hypertension, which cause most kidney failure cases.
Nephrology 2050: an evidence-informed roadmap from precision prevention to kidney regeneration.
This review covers the future of kidney health: precision prevention, AI-driven care, and regenerative medicine. It discusses how to use molecular biology to prevent kidney failure.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
This first-in-human study will test the safety and drug levels of OJR520 in adults with kidney disease.
A Natural History Study of Metabolic Sizing in Health and Disease
This study will look at how metabolism differs between people with kidney disease and healthy adults. It uses a combination of-calorimetry and genetic testing.
Monotypic IgA nephropathy: A large health system experience
This study of 105 patients with IgA nephropathy found that using a different-sized Biopsy needle did not affect kidney damage scores. The study lasted 3 years.
AI-DMRS Model May Predict Cardiometabolic Multimorbidity and Other Multisystemic Chronic Disease Clusters in the Preclinical Stage
This study used AI to predict multi-organ disease risk in 100 patients. The model was trained on data from 5 different hospitals.
Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation.
SGLT2 inhibitors may reduce kidney decline in older adults with diabetes. This study used data from Japan to compare SGLT2i with DPP4i in patients aged 75+ years. The results could change how we treat older diabetics.
Retraction Note: Integrative multi-omics profiling for early diagnosis, stratification and personalized management of chronic kidney disease: a new paradigm
This paper was retracted due to errors in the original multi-omics profiling method.
Anticoagulation for atrial fibrillation in adults with advanced kidney disease: UK kidney association clinical practice guideline
This guideline covers anticoagulation for atrial fibrillation in patients with advanced kidney disease. It's a review of several trials, but no large trial covers this specific population. Use with caution in patients with low platelets or high bleeding risk.
Does Dialysis Type Matter? Re-Evaluating Prognosis in UTUC Patients Following Surgery
This review discusses using microRNAs to detect kidney cancer. It's a review of-the-literature, not a new trial.
Pneumocystis jirovecii prophylaxis with trimethoprim-sulfamethoxazole and resistance in ESBL-producing Enterobacterales bloodstream infections among kidney transplant recipients
This review discusses microRNAs for kidney cancer detection. It's a review of-the-literature, not a new trial.
Urine and Blood-Derived MicroRNAs in Patients with Kidney Cancer: A Review of Clinical Utility and Recent Developments
This review discusses microRNAs for kidney cancer detection. It's a review of-the-literature, not a new trial.